Johnson & Johnson Exits NeuWave Medical as Quantum Surgical Acquires the Oncology Ablation Leader

Recently, according to foreign media reports, Quantum Surgical has completed the acquisition of NeuWave Medical, a subsidiary of Johnson & Johnson. The financial details of the transaction have not been disclosed. Notably, the two companies willTo become a subsidiary of the newly established holding company, Precision IO Group Inc.

Image Source: FIERCE Biotech

According to Johnson & Johnson, NeuWave Medical is a leading provider of interventional oncology solutions in the United States and was acquired by Johnson & Johnson in 2016. According to the PharmCube MedTech data query, currently NeuWave14 products have been launched in the United States., including the air-cooled microwave ablation device Certus, single-use microwave ablation needles, etc., mainly used for image-guided tumor ablation therapy.

In 2020, NeuWave Medical officially entered China. Currently, itsTwo products have been launched in China.:Microwave Ablation Therapy System and Single-Use Microwave Ablation Puncture Needle.

Image Source: PharmCube Medical Device Data

In 2025, Johnson & Johnson announced it would cease operations of NeuWave Medical, and then formally decided to sell the business in September of the same year. Now, with the completion of the acquisition, Quantum Surgical will officially take over NeuWave Medical.

Quantum Surgical was founded in 2017, and since its establishment, it has always focused on developingRobotic-Assisted Surgical System for Minimally Invasive Cancer Treatment. According to the Yaoke Medical Device Data query, its core product currentlyEpione RobotThe platform has been launched in China. As the new owner, Quantum Surgical will acquire NeuWave's microwave ablation platform, which is reported to be used for percutaneous ablation procedures that utilize electromagnetic waves to heat and destroy large-volume tumors.

Image Source: PharmaSmart Medical Data

In a joint statement regarding this acquisition, the two companies stated that NeuWave Medical's technology is currently adopted by 70% of the top cancer centers in the U.S. and that the technology complements Quantum Surgical’s Epione robotic platform, which focuses on early-stage tumor treatment and provides precise guidance during percutaneous tumor ablation procedures performed by doctors.

Notably, Johnson & Johnson has implemented a series of strategic adjustments in recent years. In addition to selling NeuWave Medical, Johnson & Johnson alsoEvaluate the spin-off plan for its orthopedic business DePuy Synthes, which may beMore than 20 billion US dollarsThe price is sold directly without further division into listed portions.

After the split, Johnson & Johnson will concentrate resources and focus more onDevelopment of Six Key Growth AreasThese six fields are oncology, immunology, neuroscience, cardiovascular, surgery, and vision-related businesses.

In addition, Johnson & Johnson officially announced that it will implement by the end of 2025Reorganization of Tissues, Changing the Operational Approach of Its Business Units, Starting from January 1, 2026, it will shift globally from a regional model to a business unit-led operational model, along with a series of adjustments to its departments and leadership levels.Transition to a Business Unit-Led New Architecture, aiming to enhance organizational agility, deepen professional focus, and accelerate market responsiveness.